Cardiology: 150 CME educational programs available now

Lipid/Metabolic

Shedding Light on HDL: Myths and Controversies

May 9, 2012 11:25 EDT

Join Drs. Nicholls, Ballantyne, and Davidson as they discuss HDL and the latest clinical research in residual CV risk reduction.

Lipid/Metabolic

Lowering LDL-Cholesterol and Novel Targets to Achieve New Levels

Apr 30, 2012 14:03 EDT

Beyond statins: genetic mutations show the way. "How low can we go?" takes on a new dimension.

Lipid/Metabolic

HDL in Motion: Molecular Dynamics and Disease Pathophysiology

Apr 23, 2012 10:34 EDT

Join Dr. Arnold von Eckardstein for an in-depth view of the dynamic relationship between HDL and LDL particles and lipid homeostasis.

Lipid/Metabolic

Reducing Cardiovascular Risk in Patients With Diabetes: Focus on Multiple Therapeutic Targets

Apr 19, 2012 16:35 EDT

Join Drs. Lincoff and McGuire as they discuss PPAR-alpha and -gamma agonists and their role in cardiovascular risk reduction.

Lipid/Metabolic

Personalizing Lipid Management: Metabolism Matters -- Strategies to Increase Statin Adherence

Apr 18, 2012 09:23 EDT

Drs. Underberg, Brown, and Fazio discuss the potential for drug-drug interactions in patients on statin therapy and their impact on adherence.

Lipid/Metabolic

The Role of CETP in Reverse Cholesterol Transport: Will Its Inhibition Reverse?

Mar 29, 2012 16:45 EDT

Join Drs. Ansell and Nicholls as they discuss the latest clinical evidence on CETP inhibition and its impact on HDL-C and atherosclerosis.

Lipid/Metabolic

Personalizing Lipid Management: Complex Cases in Polypharmacy

Mar 29, 2012 16:04 EDT

Polypharmacy increases the risk of drug-drug interactions when statin therapy is initiated. Take this case-based survey on statin selection.

Lipid/Metabolic

HDL as a Protective Lipoprotein: Focus on Coronary Artery Disease

Mar 27, 2012 11:29 EDT

Join Drs. Barter and Rader as they discuss HDL's role in atherogenic disease and the factors that influence the functionality of HDL.

Lipid/Metabolic

Dyslipidemia and Residual Atherosclerotic Risk: Focus on HDL-C

Feb 27, 2012 13:15 EST

Join experts as they clarify emerging therapeutic options for treating patients with low HDL levels based on recent clinical trial data.

Lipid/Metabolic

Fellows' Corner: Residual Cardiovascular Risk and HDL — The Year in Review

Feb 14, 2012 10:42 EST

Join Dr. Nidhi Mehta as she reviews the results of this year's major trials aimed at reducing cardiovascular risk and raising HDL-C.

Lipid/Metabolic

Experts' Corner: HDL and Cardiovascular Risk—The Year in Review

Feb 3, 2012 10:01 EST

Join Drs. Rader and Blumenthal as they discuss the results of this year's major trials looking at reducing cardiovascular risk and raising HDL-C.

Lipid/Metabolic

ACS in Patients with Type 2 Diabetes: Exploring New Pathways to Reduce Cardiovascular Risk

Jan 31, 2012 11:00 EST

Join Dr. Jorge Plutzky as he discusses the potential for PPAR agonists in reducing cardiovascular risk in patients with type 2 diabetes.

Lipid/Metabolic

Is CETP Inhibition the Answer to Residual Risk? A Global Perspective

Jan 24, 2012 14:22 EST

Join Drs. Rosenson, Lüscher, and Deanfield as they discuss the potential clinical impact of AIM-HIGH and the latest CETP-inhibitor clinical trials from a global perspective.

Lipid/Metabolic

Highlights of Lipid Summit 2011

Dec 27, 2011 14:22 EST

Dr. Rader and his panel of experts, Drs. Davidson, Fazio, Orringer, and Underberg, examine the latest data on the metabolism, function, quantification, and modulation of HDL-C.

Lipid/Metabolic

Highlight on CETP: Role in Lipid Metabolism and Homeostasis

Dec 23, 2011 09:45 EST

Join Dr. Rader as he discusses whether a change in HDL cholesterol level reflects proper HDL particle function or therapeutic success.

Lipid/Metabolic

Addressing Residual Risk in the ACS Patient: Knowing the Numbers

Dec 21, 2011 08:21 EST

Join Drs. Chapman, Gotto, and Kastelein as they discuss the results of AIM-HIGH and the latest CETP-inhibitor clinical trials in HDL-targeted residual cardiovascular risk reduction.

Lipid/Metabolic

Late-Breaking Developments in the Treatment of Dyslipidemia: Are All Omega-3 Fatty Acids the Same?

2 COMMENTS - Dec 20, 2011 14:17 EST

Join our experts Drs. Miller, Schaefer, Jacobson, and Bays as they discuss current and future management of the patient with hyperlipidemia.

Lipid/Metabolic

HDL Quality: Is It a Better Target Than HDL-C?

Dec 20, 2011 11:21 EST

Join Dr. Nicholls as he discusses the clinical significance of HDL-C for residual cardiovascular risk and whether HDL functionality would be a better predictor of therapeutic success. And DISCUSS this topic with Dr. Nicholls on Medscape Discuss.

Lipid/Metabolic

Statin Therapy Case Challenge: Lipid Treatment Strategies in Patients With HIV

Dec 14, 2011 14:47 EST

Join Drs. Underberg and Waters as they discuss dyslipidemia in patients with HIV and the appropriate selection of statin therapy to avoid drug-drug interactions.

Lipid/Metabolic

HDL-C and AIM-HIGH: Does Increasing HDL-C Reduce Cardiovascular Risk?

Dec 9, 2011 14:12 EST

Join Drs. Davidson, Toth, and Boden as they discuss the results of the AIM-HIGH trial and its implications on the treatment of low HDL-C with currently available agents.

Lipid/Metabolic

HDL and CHD: New Mechanisms Targeting Risk

1 COMMENT - Dec 7, 2011 10:15 EST

Join Drs. Eckel, Ridker, and Cannon for a panel discussion on the relationship among LDL-C, low HDL-C, and therapies in development targeting residual CV risk.

Lipid/Metabolic

Statin Intolerance in the Elderly: Solutions for Complex Cases

11 COMMENTS - Nov 28, 2011 16:20 EST

Join Drs. Fuster, Barter, and Toth as they discuss the challenges of identifying statin intolerance in elderly patients and how to manage it effectively.

Lipid/Metabolic

New Directions in the Treatment of Mixed Dyslipidemia and Residual Risk

Nov 28, 2011 09:34 EST

Join our experts Drs. Ballantyne, Schaefer, Miller, and Bays as they discuss perspectives from AHA 2011 meeting on improving the standard of care for patients with dyslipidemia.

Lipid/Metabolic

Dilemmas in Diabetes and Cardiovascular Disease: Positioning PPAR Agonists to Address the Big Picture

Nov 17, 2011 15:00 EST

Join Drs. Betteridge and Charbonnel as they discuss PPAR agonists in development and their potential in cardiovascular risk reduction.

Lipid/Metabolic

Polypharmacy and Statin Selection: Reducing the Potential for Drug-Drug Interactions

1 COMMENT - Nov 7, 2011 13:14 EST

Join Drs. Foody and Dall as they discuss managing statin intolerance, drug-drug interactions, and statin therapy selection in patients with dyslipidemia.